Arcus Biosciences reports Q4 net income of $279.4M on Gilead option exercise; cash ~$1.4B post-Gilead payments

Arcus Biosciences, Inc.

2021-FY EPS reported $0.71 revenue$382,882,000

Q4 2021 revenue $354.5M (vs $9.5M Q4 2020) primarily from Gilead license revenue; full-year revenue $382.9M.
Net income Q4 $279.4M vs net loss $51.9M prior year; full-year net income $52.8M vs net loss $122.9M.
Cash, equivalents and investments $681.3M at Dec 31, 2021; plus $725M from Gilead in Jan 2022 = ~$1.4B, funding into 2026.
First patient dosed in PACIFIC-8 Phase 3 (domvanalimab + durvalumab in Stage 3 NSCLC); two more Phase 3 studies planned for 2022.
Data readouts for ARC-7 (domvanalimab/etrumadenant in NSCLC) and ARC-8 (quemliclustat in pancreatic cancer) expected 2H22.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.